|
J. Biol. Chem., Vol. 268, Issue 36, 27160-27163, 12, 1993
rho GAP of 28 kDa (GAP2), but not of 190 kDa (p190), requires Asp65 and Asp67 of rho GTPase for its activation
N Morii, N Kumagai, MS Nur-E-Kamal, S Narumiya and H Maruta
Department of Pharmacology, Kyoto University Faculty of Medicine, Japan.
Two distinct GTPase-activating proteins (GAPs), i.e. rho GAPs of 28 kDa
(GAP2) and of 190 kDa (p190), stimulate the intrinsic GTPase activity of
the rho protein. The rho GAP activity of p190 resides in its C- terminal
domain (p190C). Neither GAP2 nor p190C activates the ras GTPase. We
replaced Asp65 and Asp67 residues of rho GTPase with the corresponding ras
residues and examined whether the domain containing them is involved in its
activation by rho GAPs. Mutation of either Asp65 to Glu or Asp67 to Ser did
not change the Kd value for GTP gamma S of the rho protein. The Ser67
mutation reduced the intrinsic GTPase activity of the rho protein, while no
change was observed with the Glu65 mutation. Both mutations abolished
activation of rho GTPase by GAP2. The GAP2-dependent activation of rho
GTPase was inhibited by the addition of GTP gamma S-bound wild type rho but
not by either GTP gamma S-bound Glu65- or Ser67-rho, indicating that both
Asp65 and Asp67 are essential for interaction of rho protein with GAP2. On
the contrary, p190C activated both Glu65- and Ser67-rho GTPases to the
extent and in a dose dependence to those seen in the wild GTPase. These
results suggest that GAP2 and p190 interact with different residues or
domains of the rho GTPase for their activation.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Goodison, J. Yuan, D. Sloan, R. Kim, C. Li, N. C. Popescu, and V. Urquidi
The RhoGAP Protein DLC-1 Functions as a Metastasis Suppressor in Breast Cancer Cells
Cancer Res.,
July 15, 2005;
65(14):
6042 - 6053.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. O.-l. Ng, Z.-d. Liang, L. Cao, and T. K.-w. Lee
DLC-1 Is Deleted in Primary Hepatocellular Carcinoma and Exerts Inhibitory Effects on the Proliferation of Hepatoma Cell Lines with Deleted DLC-1
Cancer Res.,
December 1, 2000;
60(23):
6581 - 6584.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
K. Fujisawa, P. Madaule, T. Ishizaki, G. Watanabe, H. Bito, Y. Saito, A. Hall, and S. Narumiya
Different Regions of Rho Determine Rho-selective Binding of Different Classes of Rho Target Molecules
J. Biol. Chem.,
July 24, 1998;
273(30):
18943 - 18949.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Vincent, M. Brouns, M. J. Hart, and J. Settleman
Evidence for distinct mechanisms of transition state stabilization of GTPases by fluoride
PNAS,
March 3, 1998;
95(5):
2210 - 2215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Fujisawa, A. Fujita, T. Ishizaki, Y. Saito, and S. Narumiya
Identification of the Rho-binding Domain of p160ROCK, a Rho-associated Coiled-coil Containing Protein Kinase
J. Biol. Chem.,
September 20, 1996;
271(38):
23022 - 23028.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Reid, T. Furuyashiki, T. Ishizaki, G. Watanabe, N. Watanabe, K. Fujisawa, N. Morii, P. Madaule, and S. Narumiya
Rhotekin, a New Putative Target for Rho Bearing Homology to a Serine/Threonine Kinase, PKN, and Rhophilin in the Rho-binding Domain
J. Biol. Chem.,
June 7, 1996;
271(23):
13556 - 13560.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kuribara, K. Tago, T. Yokozeki, T. Sasaki, Y. Takai, N. Morii, S. Narumiya, T. Katada, and Y. Kanaho
Synergistic Activation of Rat Brain Phospholipase D by ADP-ribosylation Factor and rhoA p21, and Its Inhibition by Clostridium botulinum C3 Exoenzyme
J. Biol. Chem.,
October 27, 1995;
270(43):
25667 - 25671.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1993 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|